Skip to content
Screener

Tandem Diabetes Care TNDM Q3 2025 earnings

Reported November 6, 2025 · After market close

Revenue$249.3MMiss by $27.7M
EPS-$0.31In line
Revenue estimate$276.9M
EPS estimate-$0.31

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$266.1M
EPS estimate-$0.26

Financials

Q3 2025

Income statement

See full
Revenue$249.3M+2.2%
Gross profit$134.3M+7.7%
Operating income-$22.9M+12.4%
Net income-$21.2M+9.0%
EPS (diluted)-$0.31+11.4%

Balance sheet

See full
Cash & equivalents$91.9M+87.5%
Total debt$449.3M-13.0%
Total equity$133.0M-44.1%
Total assets$874.7M-8.7%

Cash flow

See full
CapEx$4.1M-21.9%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$820.29M-70.5%
Enterprise value$1.18B-63.7%
P/S0.8×-2.4×

Profitability

See full
Gross margin53.2%+3.4pp
Operating margin-19.5%+6.3pp
Net margin-20.2%+11.4pp

Returns & leverage

See full
Return on equity-109.7%-393pp
Debt / equity3.4×+1.2×
Current ratio2.4×-0.5×

Segments

By product

See full
Supplies and other$139.1M+8.6%
Pump$110.1M-4.1%

FAQ

When did Tandem Diabetes Care report Q3 2025 earnings?
Tandem Diabetes Care (TNDM) reported Q3 2025 earnings on November 6, 2025 after market close.
What were Tandem Diabetes Care's Q3 2025 revenue and EPS?
Tandem Diabetes Care reported revenue of $249.3M and eps of $-0.31 for Q3 2025.
Did Tandem Diabetes Care beat estimates in Q3 2025?
Revenue missed the consensus estimate of $276.9M by $27.7M. EPS beat the consensus estimate of $-0.31 by $0.00.
How did Tandem Diabetes Care's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 31.4% from $363.3M a year earlier and eps grew 13.9% from $-0.36.
Where can I find Tandem Diabetes Care's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001438133-25-000186) and the 10-Q periodic report (0001438133-25-000187) directly on SEC EDGAR. The filing index links above go to sec.gov.